Business
Caris is a precision medicine company using molecular profiling, AI, and large oncology data sets across clinical and biopharma markets.
Caris nearly doubled FY2025 revenue to $812.0M and turned FCF positive, but it still posted a $68.1M net loss and an Altman distress screen.
The read at a glance✓ Audited against SEC data
- Business mix — Precision oncologyNote
- Revenue — $812.0M, +97.0%OK
- Net income — Loss $68.1M, improvedOK
- FCF — $66.9M, positiveOK
- Stock comp — $70.0M, +275.5%Watch
- Insiders — $110K purchases / 1 saleOK
- Accounting — Altman distress; EQ safeWatch
Where the revenue comes from
Fiscal 2025, as Caris Life Sciences, Inc. reports it. History and quarterly detail are in the app.
- Cost of services - Molecular profiling services$766.7M
- Cost of services - Pharma research and development services$45.3M
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-06-05
- 10-Q · Quarterly report2026-05-08
- 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Caris Life Sciences, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.